Xilio Therapeutics, Inc.
XLO
$0.6844
-$0.0154-2.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.44% | -1.31% | 6.61% | -0.68% | 19.05% |
| Total Depreciation and Amortization | -23.34% | 32.53% | -1.57% | -14.38% | 0.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 140.07% | 1.12% | -3.68% | 4.30% | -17.57% |
| Change in Net Operating Assets | -106.71% | 1,459.86% | -83.78% | -105.04% | 621.40% |
| Cash from Operations | -149.96% | 304.69% | -3.55% | -168.52% | 289.99% |
| Capital Expenditure | -1,722.73% | -266.67% | 33.33% | 57.14% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,722.73% | -266.67% | 33.33% | 57.14% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | 100.00% | 66.67% | 99.37% |
| Issuance of Common Stock | -99.09% | -41.09% | 204,950.00% | -99.98% | 365.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 880.17% | -41.09% | 273,500.00% | -100.01% | 2,000.94% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.86% | 666.82% | 56.44% | -134.23% | 518.67% |